NDNoemi Dannecker

Noemi Dannecker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noemi Dannecker has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Brugger

    Neuropsychology Unit, Department of Neurology, University Hospital Zurich & Clinical Neuroscience Center, University of Zurich, Zurich, Switzerland

    4 shared publications
  • Luca Regli

    Department of Neurosurgery, University Hospital Zurich & Clinical Neuroscience Center University of Zurich, Zurich, Switzerland

    3 shared publications
  • Anna Steiner

    Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland

    2 shared publications
  • Dario Palpella

    School of Medicine and Surgery, University of Milano-Bicocca, via Cadore 48, Monza, 20900, Italy, 39 0264488483

    2 shared publications
  • Giacomo Cecere

    Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland

    2 shared publications
  • Johanna Maria Catharina Blom

    Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    2 shared publications

Latest Publications

  • Open Access

    An exploratory network analysis to investigate schizotypy’s structure using the ‘Multidimensional Schizotypy Scale’ and ‘Oxford-Liverpool Inventory’ in a healthy cohort

    by Pierfrancesco Sarti, Werner Surbeck, Giacomo Cecere, Noemi Dannecker, Rahel Horisberger, Nils Kallen, Wolfgang Omlor, Anna Steiner, Dario Palpella, Marius Brandenberg, et al.

    Schizophrenia spectrum disorders and schizotypy share traits across positive, negative, and disorganised domains. Instruments like the Multidimensional Schizotypy Scale (MSS) and the Oxford-Liverpool Inventory (O-LIFE) offer nuanced perspectives on schizotypy, including its expression as a personality trait and its potential clinical outcomes. This study investigates the structure of schizotypy using exploratory graph analysis (EGA) to analyse how the MSS and O-LIFE operationalise the construct in the same sample of German speakers. This approach allows comparison of their factorial structures from both statistical and clinical perspectives, while also assessing cross-cultural validity. 1059 German-speaking, healthy participants completed the MSS and O-LIFE questionnaires. EGA was conducted to identify dimensional structures within each scale, utilising the graphical lasso algorithm for network estimation and the Walktrap community detection method for clustering. Confirmatory factor analysis was used to assess model fit and reliability, using indices such as the comparative fit index and root mean square error of approximation. EGA of the MSS revealed three primary dimensions and an additional ‘dissociated’ domain. This four-dimensional model showed improved fit and reliability compared to the original model. For the O-LIFE, EGA identified a refined four-factor structure comprising: 'cognitive and behavioural disorganisation,’ ‘introversion’, ‘unusual experiences’, and ‘environmental valence’, all validated by confirmatory analyses. This study supports the multidimensional view of schizotypy, introducing new factor structures in the MSS and O-LIFE that emphasise the previously unexplored domains ‘dissociated’ and ‘environmental valence.’ These findings highlight the value of culturally adaptive tools in enhancing schizotypy assessment and intervention strategies.


  • Open Access

    Investigating the structure of Schizotypy through the “Multidimensional Schizotypy Scale” and “Oxford-Liverpool Inventory”: an Exploratory network analysis approach in the healthy population

    by Pierfrancesco Sarti, Werner Surbeck, Giacomo Cecere, Noemi Dannecker, Rahel Horisberger, Nils Kallen, Wolfgang Omlor, Anna Steiner, Dario Palpella, Nicolas Langer, et al.

    Background Schizophrenia spectrum disorders and schizotypy share traits across positive, negative, and disorganized domains. Instruments like MSS and O-LIFE provide insights into these dimensions. Despite challenges posed by cultural variations and measurement methodologies, these instruments offer nuanced perspectives on the spectrum of schizotypy, spanning from its expression as a personality trait to its potential implications in clinical settings. Methods Through an Exploratory Graph Analysis (EGA) applied to a sample of 1059 healthy subjects, we compare the resulting networks with the original factorial structure of the two questionnaires and explore how each one conceptualizes schizotypy. Comparing both models quantitatively and qualitatively these models, we seek to elucidate the unique insights provided by each instrument regarding the spectrum of schizotypy as a personality trait. Results EGA analyses unveiled a three-dimensional structure plus an additional one consisting of items related to the concept of “Disconnection”. Confirmatory factor analysis showed this four-dimensional model outperformed others. High reliability and strong factor saturation were observed for all four factors. O-LIFE’s EGA revealed a complex structure, refined to four factors removing items with low fitting indices from the scale. Confirmatory analysis validated a final model with robust reliability and well-defined factor structures across the new “Cognitive and Behavioural Disorganization”, “Introversion”, “Unusual Experiences”, and “Environmental Pressure” factors. Conclusions This study improves the understanding of schizotypy by proposing new MSS and O-LIFE factor structures via EGA. Both scales uniquely contribute to schizotypy assessment in healthy populations, warranting further research to validate and refine these new domains across diverse populations.

  • Open Access

    Screening tools for early neuropsychological impairment after aneurysmal subarachnoid hemorrhage

    by Ilari M. Rautalin, Martina Sebök, Menno R. Germans, Miikka Korja, Noemi Dannecker, Olivia Zindel-Geisseler, Peter Brugger, Luca Regli, Martin N. Stienen

    Background: Although most aneurysmal subarachnoid hemorrhage (aSAH) patients suffer from neuropsychological disabilities, outcome estimation is commonly based only on functional disability scales such as the modified Rankin Scale (mRS). Moreover, early neuropsychological screening tools are not used routinely. Objective: To study whether two simple neuropsychological screening tools identify neuropsychological deficits (NPDs), among aSAH patients categorized with favorable outcome (mRS 0—2) at discharge. Methods: We reviewed 170 consecutive aSAH patients that were registered in a prospective institutional database. We included all patients graded by the mRS at discharge, and who had additionally been evaluated by a neuropsychologist and/or occupational therapist using the Montreal Cognitive Assessment (MoCA) and/or Rapid Evaluation of Cognitive Function (ERFC). The proportion of patients with scores indicative of NPDs in each test were reported, and spearman correlation tests calculated the coefficients between the both neuropsychological test results and the mRS. Results: Of the 42 patients (24.7%) that were evaluated by at least one neuropsychological test, 34 (81.0%) were rated mRS 0—2 at discharge. Among these 34 patients, NPDs were identified in 14 (53.9%) according to the MoCA and 8 (66.7%) according to the ERFC. The mRS score was not correlated with the performance in the MoCA or ERFC. Conclusion: The two screening tools implemented here frequently identified NPDs among aSAH patients that were categorized with favorable outcome according to the mRS. Our results suggest that MoCA or ERFC could be used to screen early NPDs in favorable outcome patients, who in turn might benefit from early neuropsychological rehabilitation.


  • Open Access

    Influence of the Intensive Care Unit Environment on the Reliability of the Montreal Cognitive Assessment

    by Martin Nikolaus Stienen, Olivia Geisseler, Julia Velz, Nicolai Maldaner, Martina Sebök, Noemi Dannecker, Yannick Rothacher, Ladina Schlosser, Nicolas Roydon Smoll, Emanuela Keller, et al.

    Background: Neuropsychological screening becomes increasingly important for the evaluation of subarachnoid hemorrhage (SAH) and stroke patients. It is often performed during the surveillance period on the intensive (ICU), while it remains unknown, whether the distraction in this environment influences the results. We aimed to study the reliability of the Montreal Cognitive Assessment (MoCA) in the ICU environment. Methods: Consecutive stable patients with recent brain injury (tumor, trauma, stroke, etc.) were evaluated twice within 36 h using official parallel versions of the MoCA (ΔMoCA). The sequence of assessment was randomized into (a) busy ICU first or (b) quiet office first with subsequent crossover. For repeated MoCA, we determined sequence, period, location effects, and the intraclass correlation coefficient (ICC). Results: N = 50 patients were studied [n = 30 (60%) male], with a mean age of 57 years. The assessment's sequence [“ICU first” mean ΔMoCA −1.14 (SD 2.34) vs. “Office first” −0.73 (SD 1.52)] did not influence the MoCA (p = 0.47). On the 2nd period, participants scored 0.96 points worse (SD 2.01; p = 0.001), indicating no MoCA learning effect but a possible difference in parallel versions. There was no location effect (p = 0.31) with ΔMoCA between locations (Office minus ICU) of −0.32 (SD 2.21). The ICC for repeated MoCA was 0.87 (95% CI 0.79–0.92). Conclusions: The reliability of the MoCA was excellent, independent from the testing environment being ICU or office. This finding is helpful for patient care and studies investigating the effect of a therapeutic intervention on the neuropsychological outcome after SAH, stroke or traumatic brain injury.


  • „Chemobrain“ – Stand der Forschung und Implikationen für die klinische Neuropsychologie

    by Noemi Dannecker, Niklas Bürgi, Peter Brugger

    Zusammenfassung. „Chemobrain“ bezeichnet kognitive Defizite, die oftmals in Zusammenhang mit chemotherapeutischen Behandlungen nichtzentralnervöser Karzinomerkrankungen auftreten und bei einigen Betroffenen über Jahre persistieren. Diese Defizite entstehen aus einem Zusammenspiel verschiedener biologischer und psychologischer Faktoren und lassen sich – anders als der Name impliziert – nicht ausschließlich auf die Chemotherapie zurückführen. Neuere Studien weisen aber darauf hin, dass Zytostatika über neurotoxische Wirkungen durchaus Hirnstruktur und -funktion und damit die Kognition verändern können. Die vorliegende Arbeit stellt den aktuellen Forschungsstand zu möglichen Wirkmechanismen vor und diskutiert alternative pathogenetische Erklärungen sowie diagnostische Implikationen und therapeutische Maßnahmen. Klinisch zeigen sich Diskrepanzen zwischen subjektiven und neuropsychologisch festgestellten Defiziten, welche eine sorgfältige Differenzierung erfordern. Im Zentrum der Behandlung stehen kognitiv-behaviorale und neuropsychologische Therapien, während für medikamentöse Ansätze bislang wenig Evidenz vorliegt.

  • Open Access

    Time to be “smart”—Opportunities Arising From Smartphone-Based Behavioral Analysis in Daily Patient Care

    by Kevin Akeret, Flavio Vasella, Olivia Geisseler, Noemi Dannecker, Arko Ghosh, Peter Brugger, Luca Regli, Martin N. Stienen

    While pathologies of the central nervous system are often associated with neuropsychological deficits, adequate quantification and monitoring of such deficits remains challenging. Due to their complex nature, comprehensive neuropsychological evaluations are needed, which are time-consuming, resource-intensive, and do not adequately account for daily or hourly fluctuations of a patient’s condition. Innovative approaches are required to improve the diagnostics and continuous monitoring of brain function, ideally in the form of a simple, objective, time-saving and inexpensive tool that overcomes the aforementioned weaknesses of conventional assessments. As smartphones are widely used and integrated in virtually every aspect of our lives, their potential regarding the acquisition of data representing an individual’s behavior and health is enormous. Alterations in a patient’s physical or mental health state may be recognized as behavioral deviation from the physiological range of the normal population, but also in comparison to the patient’s individual baseline assessment. As smartphone-based assessment allows for continuous monitoring and therefore accounts for possible fluctuations or transiently occurring abnormalities in a patient’s neurologic state, it may serve as a surveillance tool in the acute setting for early recognition of complications, or in the long-term outpatient setting to quantify rehabilitation or disease progress. This may be particularly interesting for regions of the world where healthcare resources for comprehensive clinical/neuropsychological examinations are insufficient or distances to healthcare providers are long. Here, we highlight the potential of smartphone-based behavioral monitoring in healthcare.